Platelet Dynamics in COVID-19 Pathophysiology

In COVID-19, platelets occupy a central role at the interface of haemostasis and immunity. SARS-CoV-2 infection induces a hypercoagulable state characterised by heightened platelet activation, aggregation and interaction with leukocytes. This pro-thrombotic phenotype contributes to microvascular thrombosis and macrovascular events observed in severe cases. Concurrently, profound alterations in platelet production and turnover have been documented, ranging from compensatory megakaryopoiesis in the bone marrow and lungs to rapid platelet clearance in the circulation. These processes may precipitate thrombocytopenia, which correlates with disease severity and mortality. Viral proteins such as the spike and envelope engage platelet receptors directly or via immune complexes, triggering intracellular signalling cascades—among them the p38 MAPK–NF-κB axis—that amplify granule secretion, surface-marker expression and thrombin generation. In parallel, systemic inflammation elevates levels of interleukins and acute-phase reactants, further enhancing platelet-driven coagulopathy. Together, these interconnected pathways underpin both the thrombotic complications and bleeding diatheses of COVID-19 and inform strategies for antiplatelet and anticoagulant interventions.

Research from Nature Portfolio

Recent studies have delineated a critical mechanism by which the viral envelope protein binds the scavenger receptor CD36 on platelets, engaging the p38 MAPK–NF-κB pathway to drive hyperactivation and thrombosis in experimental models. Pharmacological or genetic inhibition of CD36 or p38 markedly attenuated platelet responses, highlighting a promising therapeutic axis. Complementing this, foundational work on interleukin-mediated coagulation has revealed that low physiological concentrations of IL-1β, IL-6 and IL-8 induce marked platelet spreading, granule release and altered clot viscoelasticity. This cytokine-driven platelet hyperactivity, while described in chronic inflammation, provides a conceptual framework for the heightened coagulopathy seen in SARS-CoV-2 infection.

Platelet Dynamics in COVID-19 Pathophysiology publication trend

The graph below shows the total number of articles in platelet dynamics in covid-19 pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

Platelet hyperactivation: Excessive platelet responsiveness marked by increased granule secretion, surface-marker upregulation and procoagulant activity.

Thrombocytopenia: A reduction in circulating platelet count, often reflecting accelerated consumption or clearance.

Megakaryopoiesis: The differentiation process by which megakaryocytes generate platelets in bone marrow and extramedullary sites.

CD36-p38 MAPK–NF-κB axis: A signalling cascade activated by platelet receptor CD36 engagement, culminating in pro-inflammatory and pro-thrombotic gene expression.

Receptor-binding domain (RBD): The portion of the SARS-CoV-2 spike protein that mediates attachment to host receptors, here implicated in direct platelet binding.

Integrin αIIbβ3: A major platelet surface receptor responsible for fibrinogen-mediated aggregation and implicated in RBD-driven platelet activation.

References

1. CD36 mediates SARS-CoV-2-envelope-protein-induced platelet activation and thrombosis. Nature Communications (2023).
2. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Scientific Reports (2016).
3. SARS-CoV-2 RBD and Its Variants Can Induce Platelet Activation and Clearance: Implications for Antibody Therapy and Vaccinations against COVID-19. Research (2023).
4. Hyperactivity of platelets and increased megakaryopoiesis in COVID-19 patients with acute respiratory distress syndrome. Med-X (2023).
5. Deciphering the omicron variant: integrated omics analysis reveals critical biomarkers and pathophysiological pathways. Journal of Translational Medicine (2024).